

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Alenfalk, Dahlström, Hunegnaw, Karlsson, Lemurell, Lindqvist, Skjåret, and Starke

Title: Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitory Activity

Serial No.: 10/596,731

Group Art Unit: 1624

Filed: November 16, 2006

Examiner: Mark L. Berch

Confirmation No.: 9947

Filed by EFS Web on: 8 March 2010

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

RESPONSE UNDER 37 C.F.R. §1.111

In response to the Office Action dated September 17, 2009 in regard to the above-identified patent application, Applicants respectfully request that the application be amended as follows. The period for responding to the Office Action has been extended, by enclosure of a petition and appropriate fee, to and through March 17, 2010.

Amendment if the specification begins at page 2.

Amendment of the claims begins at page 3.

Remarks begin at page 13.